Inner Mongolia Furui Medical Science (300049) Fundamentals 2026 — P/E 69.7x, Revenue Analysis | SniperIQ
Inner Mongolia Furui Medical Science (300049) is a CN-listed Healthcare company in Biotechnology with a market capitalization of ¥11.0B, trading at ¥41.70 on the SHZ. This SniperIQ fundamentals page covers Inner Mongolia Furui Medical Science's valuation (P/E 69.7x, P/B 5.6x), profitability (net margin 9.7%), revenue (¥1.6B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Inner Mongolia Furui Medical Science's market cap?
Inner Mongolia Furui Medical Science (300049) has a market capitalization of approximately ¥11.0B, trading at ¥41.70 on the SHZ. Market cap moves with the live share price.
What is Inner Mongolia Furui Medical Science's P/E ratio?
Inner Mongolia Furui Medical Science's trailing twelve-month P/E ratio is 69.7x, with a price-to-book (P/B) of 5.6x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Inner Mongolia Furui Medical Science?
Inner Mongolia Furui Medical Science runs a net profit margin of 9.7%, a gross margin of 72.9%, and an operating margin of 23.4%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Inner Mongolia Furui Medical Science generate?
Inner Mongolia Furui Medical Science reported revenue of ¥1.6B for fiscal year 2025, with net income of ¥154M and earnings per share (EPS) of 0.59. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Inner Mongolia Furui Medical Science pay a dividend?
Inner Mongolia Furui Medical Science offers a trailing dividend yield of about 0.4%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Inner Mongolia Furui Medical Science financially healthy?
Inner Mongolia Furui Medical Science carries a debt-to-equity ratio of 0.04x and a current ratio of 3.44x, with a market beta of -0.41. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Inner Mongolia Furui Medical Science a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Inner Mongolia Furui Medical Science (300049) the key facts are: market cap ¥11.0B, P/E 69.7x, revenue ¥1.6B, 52-week range 36.5-90.68. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Inner Mongolia Furui Medical Science's full fundamentals live
Get Inner Mongolia Furui Medical Science's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.